Axsome Therapeutics, Inc. (AXSM)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 73.68 |
| Open | 74.15 |
| Bid | 72.25 x 100 |
| Ask | 72.54 x 100 |
| Day's range | 72.40 - 75.95 |
| 52-week range | 55.02 - 98.40 |
| Volume | |
| Avg. volume | 744,926 |
| Market cap | 3.502B |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.45 |
| Earnings date | 05 Aug 2024 - 09 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 124.60 |
Simply Wall St.Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Investors in Axsome Therapeutics, Inc. ( NASDAQ:AXSM ) had a good week, as its shares rose 2.0% to close at US$75.68...
GlobeNewswireAxsome Therapeutics to Present at Upcoming Investor Conferences
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in two upcoming investor conferences. The presentation details are as follows: RBC Capital Markets 2024 Global Healthcare Conference, on Tuesday, May 14, at 1:35 p.m. Eastern Time. Dr. Tabu
ZacksAxsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates
Axsome's (AXSM) bottom line declines year over year in the first quarter. Strong sales of Auvelity drive revenues.
© 2024 Yahoo. All rights reserved.